196 related articles for article (PubMed ID: 37345508)
1. Switching to long-acting injectable antipsychotics: pharmacological considerations and practical approaches.
Højlund M; Correll CU
Expert Opin Pharmacother; 2023; 24(13):1463-1489. PubMed ID: 37345508
[TBL] [Abstract][Full Text] [Related]
2. Long-acting injectable antipsychotics update: lengthening the dosing interval and expanding the diagnostic indications.
Citrome L
Expert Rev Neurother; 2017 Oct; 17(10):1029-1043. PubMed ID: 28832262
[TBL] [Abstract][Full Text] [Related]
3. Letter to the Editor: Rethinking The Cost Of Antipsychotic Treatment: The Average Cost Of The Drugs Used In Turkey In 2020.
Yıldız M; Osman E
Turk Psikiyatri Derg; 2022; 33(2):146-148. PubMed ID: 35730516
[TBL] [Abstract][Full Text] [Related]
4. Cost Effectiveness of Paliperidone Long-Acting Injectable Versus Other Antipsychotics for the Maintenance Treatment of Schizophrenia in France.
Druais S; Doutriaux A; Cognet M; Godet A; Lançon C; Levy P; Samalin L; Guillon P
Pharmacoeconomics; 2016 Apr; 34(4):363-91. PubMed ID: 26883132
[TBL] [Abstract][Full Text] [Related]
5. Treatment Patterns, Health Care Resource Utilization, and Spending in Medicaid Beneficiaries Initiating Second-generation Long-acting Injectable Agents Versus Oral Atypical Antipsychotics.
Pilon D; Tandon N; Lafeuille MH; Kamstra R; Emond B; Lefebvre P; Joshi K
Clin Ther; 2017 Oct; 39(10):1972-1985.e2. PubMed ID: 28919292
[TBL] [Abstract][Full Text] [Related]
6. Antipsychotic Adherence and Rehospitalization in Schizophrenia Patients Receiving Oral Versus Long-Acting Injectable Antipsychotics Following Hospital Discharge.
Marcus SC; Zummo J; Pettit AR; Stoddard J; Doshi JA
J Manag Care Spec Pharm; 2015 Sep; 21(9):754-68. PubMed ID: 26308223
[TBL] [Abstract][Full Text] [Related]
7. Long-acting injectable antipsychotics (LAIs) for maintenance treatment of bipolar and schizoaffective disorders: A systematic review.
Pacchiarotti I; Tiihonen J; Kotzalidis GD; Verdolini N; Murru A; Goikolea JM; Valentí M; Aedo A; Vieta E
Eur Neuropsychopharmacol; 2019 Apr; 29(4):457-470. PubMed ID: 30770235
[TBL] [Abstract][Full Text] [Related]
8. Maintenance Treatment With Long-Acting Injectable Antipsychotics for People With Nonaffective Psychoses: A Network Meta-Analysis.
Ostuzzi G; Bertolini F; Del Giovane C; Tedeschi F; Bovo C; Gastaldon C; Nosé M; Ogheri F; Papola D; Purgato M; Turrini G; Correll CU; Barbui C
Am J Psychiatry; 2021 May; 178(5):424-436. PubMed ID: 33596679
[TBL] [Abstract][Full Text] [Related]
9. Comparative effectiveness of long-acting injectable antipsychotics in patients with schizophrenia in Japan.
Okada Y; Inada K; Akazawa M
Schizophr Res; 2023 Feb; 252():300-308. PubMed ID: 36706475
[TBL] [Abstract][Full Text] [Related]
10. [Clinical pharmacokinetics and pharmaceutical forms of long-acting injectable antipsychotics].
Kyziridis TC
Psychiatriki; 2022 Jun; 33(2):139-148. PubMed ID: 34390562
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness Analysis of Aripiprazole Once-Monthly for the Treatment of Schizophrenia in the UK.
Tempest M; Sapin C; Beillat M; Robinson P; Treur M
J Ment Health Policy Econ; 2015 Dec; 18(4):185-200. PubMed ID: 26729007
[TBL] [Abstract][Full Text] [Related]
12. Long-Acting Injectable Second-Generation Antipsychotics: An Update and Comparison Between Agents.
Jann MW; Penzak SR
CNS Drugs; 2018 Mar; 32(3):241-257. PubMed ID: 29569082
[TBL] [Abstract][Full Text] [Related]
13. Long-Acting Injectable Second-Generation Antipsychotics vs Placebo and Their Oral Formulations in Acute Schizophrenia: A Systematic Review and Meta-Analysis of Randomized-Controlled-Trials.
Wang D; Schneider-Thoma J; Siafis S; Burschinski A; Dong S; Wu H; Zhu Y; Davis JM; Priller J; Leucht S
Schizophr Bull; 2024 Jan; 50(1):132-144. PubMed ID: 37350486
[TBL] [Abstract][Full Text] [Related]
14. [Cost-effectiveness analysis of schizophrenic patient care settings: impact of an atypical antipsychotic under long-acting injection formulation].
Llorca PM; Miadi-Fargier H; Lançon C; Jasso Mosqueda G; Casadebaig F; Philippe A; Guillon P; Mehnert A; Omnès LF; Chicoye A; Durand-Zaleski I
Encephale; 2005; 31(2):235-46. PubMed ID: 15959450
[TBL] [Abstract][Full Text] [Related]
15. Evaluating the efficacy and safety of the currently available once-every-two months long-acting injectable formulations of aripiprazole for the treatment of schizophrenia or as a maintenance monotherapy for bipolar I disorder in adults.
Samalin L; Boudieu L; Llorca PM
Expert Rev Neurother; 2024 Mar; 24(3):291-298. PubMed ID: 38299536
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetic Characteristics of Long-Acting Injectable Antipsychotics for Schizophrenia: An Overview.
Correll CU; Kim E; Sliwa JK; Hamm W; Gopal S; Mathews M; Venkatasubramanian R; Saklad SR
CNS Drugs; 2021 Jan; 35(1):39-59. PubMed ID: 33507525
[TBL] [Abstract][Full Text] [Related]
17. Dosing and switching strategies for paliperidone palmitate: based on population pharmacokinetic modelling and clinical trial data.
Samtani MN; Gopal S; Gassmann-Mayer C; Alphs L; Palumbo JM
CNS Drugs; 2011 Oct; 25(10):829-45. PubMed ID: 21936586
[TBL] [Abstract][Full Text] [Related]
18. Long-Acting Injections in Schizophrenia: a 3-Year Update on Randomized Controlled Trials Published January 2016-March 2019.
Peters L; Krogmann A; von Hardenberg L; Bödeker K; Nöhles VB; Correll CU
Curr Psychiatry Rep; 2019 Nov; 21(12):124. PubMed ID: 31745659
[TBL] [Abstract][Full Text] [Related]
19. Personalized switching from oral to long-acting injectable second-generation antipsychotics in schizophrenia treatment using pharmacokinetic considerations.
Schoretsanitis G; Meyer JM; Conca A; Hiemke C
Expert Opin Drug Metab Toxicol; 2023 Apr; 19(4):189-202. PubMed ID: 37259573
[TBL] [Abstract][Full Text] [Related]
20. Long-acting second-generation injectable antipsychotics for the maintenance treatment of bipolar disorder: a narrative review.
Belge JB; Sabbe BGCC
Expert Opin Pharmacother; 2024 Feb; 25(3):295-299. PubMed ID: 38465894
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
